The transcription factor cAMP response element (CRE)-binding protein (CREB) plays an essential role in the induction of many forms of long-term synaptic plasticity. Levels of CREB1, the Aplysia homolog of CREB, show sustained elevations for several hours after the induction of long-term synaptic facilitation (LTF). Furthermore, CREB1 binds to the promoter of its own gene. These results suggest the existence of a CREB1-positive feedback loop that contributes to the consolidation of LTF. In the present study, we provide a detailed, quantitative characterization of the dynamics of CREB1 mRNA and protein as well as CREB1 phosphorylation after LTF induction. Injections of CRE oligonucleotides prevented the increase in CREB1 in response to 5-HT, corroborating the existence of the CREB1 feedback loop. This loop probably sustains CRE-dependent gene transcription, which remains elevated for at least 12 h after LTF induction. LTF is blocked by injection of CREB1 antibody after the induction phase, suggesting that the CREB1-positive feedback is required for consolidation of LTF.
Introduction
Long-term memory and plasticity, including long-term synaptic facilitation (LTF) of the Aplysia sensorimotor synapse, depend on the activation of transcription factors that regulate genes necessary for synaptic plasticity. Recently, it has become clear that among the genes regulated by transcription factors are those coding for transcription factors themselves. One such gene is creb1 (Mohamed et al., 2005) , the Aplysia homolog of mammalian creb (Bartsch et al., 1998) . The neuromodulator serotonin (5-HT), which is released in response to sensitizing stimuli (Levenson et al., 1999; Marinesco and Carew, 2002) , leads to phosphorylation and activation of cAMP response element (CRE)-binding protein 1 (CREB1) through activation of protein kinase A (PKA) (Bartsch et al., 1998; Müller and Carew, 1998) . CREB1-mediated gene expression is required for induction of LTF (Dash et al., 1990; Bartsch et al., 1998) . However, the requirement for gene expression is not limited to the induction phase. The necessity of prolonged transcription and translation persists for at least 7-9 h after induction (Alberini et al., 1994; O'Leary et al., 1995) .
Previous studies (Bartsch et al., 1998) showed that levels of CREB1 increased after whole-animal exposure to solutions containing 5-HT, suggesting that CREB1 may be regulated during LTF. We previously extended these findings by discovering a CRE in the promoter region of the creb1 gene (Mohamed et al., 2005) . Moreover, treatment of ganglia with five pulses of 5-HT, a protocol commonly used to induce LTF (Montarolo et al., 1986; Mauelshagen et al., 1998) , resulted in enhanced recruitment of CREB1 to its promoter (Mohamed et al., 2005) . These observations suggested that CREB1 can regulate its own expression, giving rise to a CREB1-positive feedback loop. The presence of such a loop could result in a prolonged increase in creb1 expression and a consequent increase in CREB1-mediated transcription, which could extend beyond LTF induction. The goal of the present study was to characterize the time course of expression of creb1 after 5-HT treatment and to investigate the functional significance of the CREB1 feedback loop for the consolidation of LTF.
Materials and Methods
Tissue preparation and pharmacological treatment. For each measurement of mRNA, two naive animals were anesthetized by injection of isotonic MgCl 2 (0.5 ml/g), and the two bilaterally symmetric pairs of pleuralpedal ganglia were surgically isolated. To obtain sufficient RNA for quantitative reverse transcription PCR (qRT-PCR), a ganglion from the right side of one animal and one from the left side of the second animal were grouped together. The two remaining ganglia formed a second group. Each group was then randomly assigned to receive either a control (vehicle) or a 5-HT treatment. For Western blot analysis, the left and right pleural-pedal ganglia from one animal were randomly assigned to receive either a control (vehicle) or a 5-HT treatment. After trimming of the connective tissue sheath in isotonic MgCl 2 :artificial seawater (ASW; 1:1 v/v), ganglia in both groups were rinsed with modified L15:ASW (1:1 v/v) and rested at 18°C for 1-2 h. Subsequently, groups were treated with five 5 min pulses of either vehicle (L15:ASW) or 50 M 5-HT with an interpulse interval of 20 min. Either immediately or at the indicated times after treatment, ganglia were rinsed with L15:ASW, rapidly frozen on dry ice, and stored at Ϫ80°C until further processing. The composition of ASW and modified L15 has been published previously (Zhang et al., 1997; Antzoulatos et al., 2003) .
qRT-PCR analysis of CREB1 mRNA. Aplysia pleural ganglia were treated with five 5 min pulses of either vehicle (L15:ASW) or 50 M 5-HT with an interpulse interval of 20 min. Total RNA was isolated from frozen pleural ganglia using Trizol (Invitrogen, Carlsbad, CA) and treated with RNase-free DNase I to remove any contaminating genomic DNA. Quantification of mRNA was done by qRT-PCR as described previously (Mohamed et al., 2005) .
Western blots. Pleural-pedal ganglia were lysed at various time points (0, 1, 2, 5, 12, and 24 h) after the end of treatment with vehicle or 5-HT in ice-cold buffer containing the following (in mM): 10 EDTA, 20 Tris, pH 7.5, 1 Na orthovanadate, 1 DTT, 2 NaF, 2 NaPPi, 0.5 okadaic acid, 1 PMSF, 1% SDS, 1% protease inhibitor cocktail (Sigma, St. Louis, MO) and stored at Ϫ20°C until further use. Thirty micrograms of Aplysia pleural-pedal extract from each group were resolved using SDS-PAGE. Protein samples were transferred to a nitrocellulose membrane. The membrane was probed with anti-phospho-ApCREB1 (anti-pCREB1; 1:1000) followed by incubation with peroxidase-conjugated secondary antibody (1:2000; Zymed, San Francisco, CA). Immunoreactive bands were visualized by ECL (GE Healthcare, Pittsburgh, PA) and analyzed with ImageQuant 5.0 software. The same membrane was stripped and reprobed with anti-total ApCREB1 (anti-tCREB1) antibody (1:500). The anti-tCREB1 antibodies were raised by a commercial vendor (Genemed Synthesis, South San Francisco, CA) against the Ser 85 -phosphorylated and the unphosphorylated versions of the bovine serum albuminconjugated CREB1 peptide KKRREILTRRPSYRK (Mohamed et al., 2005) . An antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:2000; IMGENEX, San Diego, CA) was used to provide a loading control. Immunoreactive bands were visualized by ECL and analyzed with ImageQuant 5.0 software.
Antibody injections and immunofluorescence analysis. Rabbit IgG or anti-tCREB1 antibody, which was also used in Western blots and immunofluorescence analyses, was injected at 0.5 g/l in 100 mM KCl-0.1% injection dye (Alexa 488 -10 kDa dextran or Fluorescein-70 kDa dextran). Sensory neurons (SNs) were injected either 2 h before or 1 h after 5-HT treatment, as indicated. At various time points after the end of treatment, cells were processed for immunofluorescence analysis using a Cy3-conjugated secondary antibody, as described by Chin et al. (1999) .
For immunofluorescence analysis, Aplysia sensory neurons were cultured as described previously (Schacher and Proshansky, 1983; . Cultures were treated with five 5 min pulses of either vehicle (L15:ASW) or 50 M 5-HT with an interpulse interval of 20 min. At various time points after the end of treatment, cells were fixed in a solution of 4% paraformaldehyde in PBS containing 30% sucrose and blocked for 30 min at room temperature in Superblock blocking buffer (Pierce, Holmdel, NJ)/0.2% Triton X-100/3% normal goat serum. Subsequently, fixed cells were incubated overnight at 4°C with anti-tCREB1 antibody (1:500) or anti-pCREB1 antibody (1:500). Secondary antibody (goat anti-rabbit secondary antibody conjugated to Cy-3; 1:200 dilution; Jackson ImmunoResearch, West Grove, PA) was applied for 1 h at room temperature. Images were obtained with a Bio-Rad (Hercules, CA) 1024 MP confocal microscope using a 60ϫ oil immersion lens. A z-series of optical sections through the cell body (0.5 m increments) was taken, and the section through the middle of the nucleus was used for analysis of mean fluorescence intensity with the MetaMorph Offline software (Universal Imaging Corporation, West Chester, PA). Five to 10 neurons on each coverslip were analyzed, and measurements from neurons on the same coverslip were averaged.
For the experiments that examined levels of total CREB1 in the nucleus after blocking cytoplasmic CREB1, the anti-tCREB1 antibody or purified rabbit IgG (control) (both at 0.5 g/l) was injected into the cytoplasm of sensory neurons immediately after 5-HT treatment. Dextranconjugated fluorescein (70 kDa) was included in the injection buffer to monitor the efficiency and locus of injection. Two hours later, cells were processed for immunofluorescence analysis using anti-tCREB1 antibody (the same antibody used for injections) as primary antibody, followed by Cy-3-conjugated secondary antibody.
For the experiments that examined levels of initial phosphorylation of CREB1 in the nucleus after blocking cytoplasmic CREB1, anti-tCREB1 antibody or purified rabbit IgG was injected into the cytoplasm of sensory neurons 2 h before treatment with 5-HT or vehicle. Immediately after the end of treatment, cells were fixed and processed for immunofluorescence analysis using anti-pCREB1 antibody as primary antibody, followed by Cy-3-conjugated secondary antibody.
Sensory neurons were imaged through confocal microscopy using the blue and green lines of a Kr/Ar laser in sequential mode at the minimal required power for excitation of fluorescein (injection dye) and Cy-3 (immunoreactivity for total CREB1). Cells were excluded from further analysis if fluorescein signal was detected in the nucleus. In antibodyinjected cells, only Cy-3 immunofluorescence in the cell nucleus was analyzed. For quantification of nuclear total CREB1 staining, the nuclear membrane was first identified using the distribution of fluorescein. Because antibodies do not cross the nuclear membrane (Ohno et al., 1998) , nuclear immunofluorescence is a measure of endogenous nuclear CREB1. Immunofluorescence analysis was performed in a "blind" manner.
Oligonucleotide injection. CRE (5Ј-GGCCTCCTTGGCTGACGTCA-GAGAGAGAGTTCTGCA-3Ј) or mutated (control) (5Ј-GGCCTCCTT-GGCCTTAAGTGGAGAGAGAGTTCTGCA-3Ј) oligonucleotides (IDT, San Jose, CA) were dissolved in 10 mM Tris, pH 7.3, 100 mM KCl, 1% dextran-conjugated Alexa 488 (10 kDa) to a final concentration of 5 g/ml. Oligonucleotide sequences were obtained from Dash et al. (1990) . Nucleotides in bold correspond to the CRE sequence or its mutated control. Oligonucleotides were pressure injected into sensory neurons immediately after the end of treatment with either five pulses of 5-HT or vehicle. Five hours later, cells were processed for immunofluorescence using anti-tCREB1 antibody, followed by Cy-3-conjugated secondary antibody. The experimenter performing the injections and subsequent immunofluorescence analysis was "blind" to the identity of group treatment.
CRE-enhanced green fluorescent protein reporter. A CRE-enhanced green fluorescent protein (EGFP) reporter vector was prepared from the previously used CRE-lacZ vector (Kaang et al., 1993) . To monitor CREdependent transcription in individual cultured sensory neurons, the lacZ gene was excised from the vector with HindIII and BamHI restriction enzymes (Promega, Madison, WI) and then replaced with the EGFP gene cloned from the pNEX3-EGFP vector (gift from B. Kaang, Seoul National University, Seoul, South Korea). Cultured sensory neurons were treated with either 5-HT or vehicle as described above. Either 2 or 12 h after the end of the treatment, neurons were injected with the CRE-EGFP expression vector (1 g/l) in injection buffer containing dextran-conjugated Texas Red fluorescence marker (70 kDa) to monitor the efficiency and locus of injection. Five hours after vector injection (i.e., either 7 or 17 h after the end of the treatment), cells were fixed with paraformaldehyde and processed for immunofluorescence analysis. Confocal optical sections through the middle of the nucleus were obtained and analyzed for mean fluorescence intensity. EGFP signal in the cytoplasm and red fluorescence from injection dye in the nucleus were determined by tracing the outline of the cell body and nucleus. Mean fluorescence intensity for EGFP in the cytoplasm was normalized to the amount of plasmid injected, indicated by the intensity of injected fluorescent dye in the nucleus. The normalized EGFP expression in 5-HT-treated cells was compared with that from vehicle-treated cells.
Electrophysiology. Sensorimotor cocultures were prepared as described previously . EPSPs were recorded from motor neurons with 10 -15 M⍀ sharp electrodes filled with 3 M potassium acetate. Neurons with resting membrane potential more positive than Ϫ40 mV and input resistance Ͻ10 M⍀ were excluded. Stimulation of presynaptic sensory neurons was performed extracellularly using a blunt patch electrode filled with modified L15-ASW. For statistical analysis, the amplitude of the EPSP was measured during the pretest and 24 h after exposure to 5-HT or vehicle (post-test), and the post/pre ratio was formed. Data acquisition was performed using pClamp (Molecular Devices, Union City, CA). Purified anti-tCREB1 antibody (0.5 g/l) or rabbit IgG (0.5 g/l) in injection buffer (100 mM KCl, 0.1% Alexa 488 -10 kDa dextran) was pressure injected in the cytoplasm of sensory neurons 1 h after the end of 5-HT treatment using the Eppendorf (Westbury, NY) microinjection system. The efficiency of the injection was monitored with a fluorescence microscope. The experimenter performing the electrophysiological testing was "blind" to the identity of the antibody injected. After the end of the 24 h posttest, a subset of cocultures injected with anti-CREB1 or IgG antibody was fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in blocking buffer for 30 min, and incubated with goat anti-rabbit secondary antibody conjugated to Cy-3 to visualize the intracellular localization of the injected primary antibody.
Results
CREB1 mRNA and protein levels in ganglia are increased for at least 24 h after induction of LTF To quantify the dynamic changes in levels of CREB1 mRNA and protein, we used qRT-PCR and Western blots. After treatment of paired pleural-pedal ganglia with five pulses of either vehicle or 5-HT, pleural ganglia were collected and frozen either immediately or 1, 2, 5, 12, or 24 h after the last treatment pulse. Compared with time-alone matched controls, CREB1 mRNA levels were significantly increased at all time points investigated ( Fig.  1 A) (mean percentage control Ϯ SEM: immediately, 144 Ϯ 12.7, t 13 ϭ 2.8, p Ͻ 0.05; 1 h, 152.9 Ϯ 27.7, t 13 ϭ 2.7, p Ͻ 0.05; 2 h, 159.3 Ϯ 14.1, t 13 ϭ 4.3, p Ͻ 0.001; 5 h, 204.2 Ϯ 16.9, t 13 ϭ 4.3, p Ͻ 0.001; 12 h, 155.5 Ϯ 17.7, t 6 ϭ 4.7, p Ͻ 0.01; 24 h, 172.6 Ϯ 17.0, t 6 ϭ 5.7, p Ͻ 0.01).
Next, Western blot analyses of lysates from pleural-pedal ganglia were performed to determine whether the observed changes in mRNA were associated with changes in protein levels ( Fig. 1)  (Fig. S1 A, available at www.jneurosci.org as supplemental material). Compared with time-alone matched controls, total CREB1 protein levels from pleural-pedal ganglia were also significantly increased at all time points investigated (Fig. 1 B) (mean percentage control Ϯ SEM: immediately, 185.0 Ϯ 24.9, t 5 ϭ 4.468, p Ͻ 0.01; 1 h, 136.3 Ϯ 14.8, t 5 ϭ 7.681, p Ͻ 0.001; 2 h, 169.3 Ϯ 19.9, t 7 ϭ 3.448, p Ͻ 0.05; 5 h, 184.4 Ϯ 23.3, t 7 ϭ 3.879, p Ͻ 0.01; 12 h, 121.4.5 Ϯ 3.5, t 4 ϭ 3.322, p Ͻ 0.05; 24 h, 133.6 Ϯ 15.0, t 4 ϭ 2.170, p Ͻ 0.05). These results indicate that CREB1 itself is one of the proteins with increased expression that is associated with LTF, and that these changes occur rapidly and persist for at least 24 h.
Phosphorylation of CREB1 in ganglia is enhanced for at least 24 h after 5-HT treatment 5-HT-induced increase in CREB1 expression lasts for at least 24 h. However, for a CREB1 feedback loop to be functional, CREB1 needs to be phosphorylated. Therefore, we examined the dynamics of 5-HT-induced CREB1 phosphorylation at Ser-85 (equivalent to Ser-133 in vertebrate CREB) using a phosphospecific antibody (Mohamed et al., 2005) . Compared with timealone matched controls, phospho-CREB1 (pCREB1) protein levels were significantly elevated for all but one time point (Fig. 1C ) Figure 1 . Dynamics of CREB1 mRNA and protein, CREB1 phosphorylation, and CRE-dependent gene transcription after 5-HT treatment. A, Summary data from qRT-PCR. CREB1 mRNA was rapidly and persistently elevated for at least 24 h after treatment with 5-HT that produces long-term facilitation. B, Total CREB1 protein levels were also persistently elevated for at least 24 h after 5-HT treatment. C, Dynamic changes of phosphorylated CREB1 after 5-HT treatment. D1, D2, Immunofluorescence staining for total-CREB1. D1, Immunoreactivity for total CREB1 in sensory neurons 2 h after vehicle or 5-HT treatment. Scale bar, 20 m. D2, CREB1 immunoreactivity increased in both cell body and nucleus 2 h after 5-HT treatment, compared with vehicle-treated control (*p Ͻ 0.05). E1, E2, CRE-mediated EGFP expression is enhanced after five pulses of 5-HT for at least up to 12 h. E1, Representative images of cells injected 12 h after 5-HT or vehicle and fixed 5 h later. Texas Red-dextran was added to the injection buffer to confirm nuclear injection. Scale bar, 20 m. E2, EGFP expression was increased in neurons injected either 2 or 12 h after 5-HT treatment, compared with controls (*p Ͻ 0.05).
( 1C) (Fig. S1 B, available at www.jneurosci.org as supplemental material). An initial peak was followed by a dramatic drop, a subsequent rapid recovery back to high levels, and a final drop to sustained phosphorylation level at ϳ150% of controls. The mechanisms and the significance of these dynamics are unclear. However, the results indicate that phosphorylation of CREB1 is enhanced for a prolonged period after treatment and therefore CREB1 could participate in a positive feedback loop.
Total and phosphorylated CREB1 levels are increased in sensory neurons after 5-HT treatment
To confirm that the observed increase of both total and phosphorylated CREB1 in the ganglia is also present in the subpopulation of SNs, which are the presynaptic sites of plasticity, we examined levels of CREB1 protein in cultured SNs using immunofluorescence and confocal microscopy. Two hours after the end of treatment with 5-HT, total CREB1 protein levels were increased in both cell body and nucleus. Compared with vehicle-treated controls, 5-HT-treated cells showed a 44 Ϯ 16% increase in tCREB1 immunofluorescence in the cell body and a 49 Ϯ 24% increase in the nucleus (Fig. 1 D) (cell body staining, t 3 ϭ 3.515, p Ͻ 0.05; nuclear staining, t 3 ϭ 3.323, p Ͻ 0.05; representing a total of 23 vehicle-treated neurons and 24 5-HT-treated neurons). These results indicate that the changes in CREB1 protein measured in ganglia are recapitulated in SNs. Moreover, not only are levels of total CREB1 elevated, but nuclear levels of phospho-CREB1 are also elevated (mean percentage control Ϯ SEM: 123.2 Ϯ 6, t 3 ϭ 3.182, p Ͻ 0.05, representing a total of 26 vehicle-treated neurons and 27 5-HT-treated neurons) (Fig. S2 , available at www. jneurosci.org as supplemental material). Levels of phospho-CREB1 in the cytoplasm and processes were extremely low compared with nuclear levels, indicating that CREB1 phosphorylation is primarily a nuclear event.
A CREB1 feedback loop regulates expression of CREB1 after 5-HT treatment
What mechanisms regulate the increased expression of CREB1 after LTF induction? Previous work showed that CREB1 can bind to the CRE in its own promoter region and that this binding is increased after treatment with 5-HT (Mohamed et al., 2005) . To examine whether the enhancement of CREB1 expression after 5-HT is regulated by CREB1 itself, we injected mutated (control) or CRE oligonucleotides in sensory neurons immediately after treatment with 5-HT or vehicle and examined the effect on CREB1 expression 5 h later through immunofluorescence analysis. The CRE oligonucleotides injected in excess should compete with endogenous sites for CREB1 binding and therefore block CREB1-dependent transcription. Results indicated that injection of CRE oligonucleotides blocked the 5-HT-induced increase in CREB1 expression [normalized to control group (mutated plus vehicle): CRE plus 5-HT, 93.33 Ϯ 7.72%; mutated plus 5-HT, 122.02 Ϯ 5.66%; CRE plus vehicle, 103.09 Ϯ 4.85%]. One-way ANOVA indicated a significant difference between the three groups (F (2,18) ϭ 6.503; p Ͻ 0.05). Subsequent pair-wise comparisons using Student-Newman-Keuls post hoc tests indicated that CRE oligonucleotides blocked 5-HT-induced increase in CREB1 (mutated plus 5-HT vs CRE plus 5-HT, q ϭ 3.51; p Ͻ 0.05) (Fig. S3 , available at www.jneurosci.org as supplemental material). These results provide direct evidence that CREB1 drives its own expression and support the existence of a CREB1-positive feedback loop during consolidation of longterm facilitation.
CRE-dependent gene transcription is increased at least up to 12 h after 5-HT treatment
What is the function of increased CREB1 expression? We reasoned that if total and phosphorylated CREB1 levels are persistently elevated after 5-HT treatment, CRE-mediated transcription should be elevated as well. To directly measure CREmediated transcription, we injected a CRE-EGFP reporter construct in cultured SNs 2 or 12 h after exposure to five 5 min pulses of either 5-HT or vehicle. Five hours after injection (corresponding to either 7 or 17 h after the end of treatment), cells were fixed and analyzed for EGFP expression. Compared with vehicle-treated cells, 5-HT-treated cells showed increased EGFP expression at both 7 h (Fig. S4 , available at www.jneurosci.org as supplemental material) and 17 h (Fig. 1 E) (mean percentage control Ϯ SEM: 7 h, 287.77 Ϯ 35.14, t 3 ϭ 4.51, p Ͻ 0.05; 17 h, 151.72 Ϯ 8.74, t 3 ϭ 4.14, p Ͻ 0.05). These results agree with the persistent elevation and phosphorylation of CREB1 and provide direct evidence that CRE-mediated transcription is not limited to the induction phase of LTF.
Sequestering cytoplasmic, including newly synthesized, CREB1 after 5-HT treatment attenuates LTF
To further investigate the functional role of increased CREB1 and the CREB1 feedback loop in LTF, we injected anti-tCREB1 antibody in the cytoplasm of SNs after the end of 5-HT treatment and examined the effect on 24 h LTF. Briefly, after assessment of basal synaptic strength, sensorimotor cocultures were treated with five pulses of vehicle or 5-HT. One hour after the end of treatment, anti-tCREB1 antibody or purified IgG (control) was injected into the sensory neuron. A fluorescent dye (Alexa 488-dextran; 10 kDa) was coinjected to help determine the locus and efficiency of injections (Fig. 2 A2) . The extent of LTF was assessed 24 h after 5-HT, during the post-test (Fig. 2 A3,A4 ). One-way ANOVA indicated a significant difference among the four groups (mean percentage post/pre Ϯ SEM: IgG-alone, 86.1 Ϯ 5.6, n ϭ 3; IgG plus 5-HT, 142.3 Ϯ 12.5, n ϭ 7; anti-tCREB1-alone, 78.3 Ϯ 14.4, n ϭ 3; anti-tCREB1 plus 5-HT, 103.0 Ϯ 5.7, n ϭ 4; F (3,16) ϭ 6.3; p Ͻ 0.01). Subsequent pair-wise comparisons using StudentNewman-Keuls post hoc tests indicated that 5-HT induced significant facilitation in the IgG-injected cocultures (q ϭ 4.53; p Ͻ 0.05) but not in the anti-tCREB1-injected cocultures (q ϭ 1.8; p Ͼ 0.05). Moreover, the IgG plus 5-HT group was significantly different from the anti-tCREB1 plus 5-HT group (q ϭ 3.49; p Ͻ 0.05). These results suggest that disruption of the CREB1 feedback loop through sequestration of cytoplasmic, including newly synthesized, CREB1 impaired LTF. Injection of IgG or anti-tCREB1 antibody alone did not significantly affect synaptic transmission over a 24 h period (q ϭ 0.53; p Ͼ 0.05) (Fig. 2 A4 ) . Therefore, blocking cytoplasmic, including newly synthesized, CREB1 through antibody injection significantly impaired LTF without affecting basal transmission.
The interpretation of the electrophysiology experiment de-scribed above relies on three assumptions pertaining to the cytoplasmic injection of anti-tCREB1 antibody: (1) antibody injection blocks the CREB1 feedback loop; (2) antibody injection does not affect resting levels of nuclear CREB1; and (3) antibody injection does not interfere with the regulation of preexisting nuclear CREB1. We performed experiments to test each of these assumptions. We first examined whether injection of anti-tCREB1 antibody disrupted the CREB1 feedback loop. With the loop intact, treatment with 5-HT should result in increased levels of CREB1 in the nucleus (Fig. 1 D) . We therefore injected SNs with either control IgG or anti-tCREB1 antibody immediately after the end of treatment with either 5-HT or vehicle, and we assayed levels of CREB1 in the nucleus 2 h later. Results showed that injection of anti-tCREB1 antibody blocked 5-HT-induced increase in nuclear CREB1 (normalized to IgG plus vehicle: anti-tCREB1 plus 5-HT, 101.9 Ϯ 7.9%; IgG plus 5-HT, 133.5 Ϯ 8.8%; anti-tCREB1 plus vehicle, 98.3 Ϯ 7.6%) (Fig. 2 B) . One-way ANOVA indicated a significant difference among these three groups (F (2,11) ϭ 17.144; p Ͻ 0.01). Subsequent pair-wise comparisons using StudentNewman-Keuls post hoc tests indicated that anti-tCREB1 antibody injection blocked the 5-HT-induced increase in nuclear CREB1 (anti-tCREB1 plus 5-HT vs IgG plus 5-HT, q ϭ 6.204; p Ͻ 0.05). These results suggest that cytoplasmic injection of anti-tCREB1 antibody after 5-HT treatment disrupts the CREB1-positive feedback loop.
To test the second assumption that injection of anti-tCREB1 antibody did not affect resting levels of nuclear CREB1, we injected anti-tCREB1 antibody or IgG in the cytoplasm of sensory neurons and assayed levels of nuclear CREB1 24 h after injection. It is possible to measure nuclear CREB1 using the same antibody for immunostaining as used for cytoplasmic injection, because the anti-tCREB1 antibody injected into the cytoplasm did not enter the nucleus. This was indicated by the lack of nuclear CREB1 staining in cells injected with anti-tCREB1 antibody in the cytoplasm, fixed and permeabilized 24 h later, and stained with a secondary antibody only (Fig. 2 A2) (n ϭ 4). When nuclear levels of CREB1 were measured 24 h after cytoplasmic injection of anti-tCREB1 antibody, we found no difference in nuclear CREB1 levels between anti-tCREB1-injected and IgG-injected cells (in arbitrary units: IgG, 112.1 Ϯ 7.4; 111.3 Ϯ 10.8 ; n ϭ 3 experiments encompassing 45 cells; t 2 ϭ 0.293; p Ͼ 0.05). Therefore, antibody injection does not affect resting levels of nuclear CREB1.
To examine the third assumption that anti-tCREB1 antibody injection does not interfere with the regulation of preexisting nuclear CREB1, we injected anti-tCREB1 antibody in SNs 2 h before treatment with either vehicle or 5-HT and measured levels of nuclear pCREB1 immediately after treatment. We found that 5-HT induced an increase in levels of nuclear pCREB1 despite the antibody injection (normalized to anti-tCREB1 plus vehicle: anti-tCREB1 plus 5-HT, 118.7 Ϯ Figure 2 . Blocking cytoplasmic, including newly synthesized, CREB1 impaired LTF and associated increase in nuclear CREB1. A1, Protocol for control IgG or anti-tCREB1 antibody injection and electrophysiological testing. Antibodies were injected in the cytosol of sensory neurons 1 h after the end of treatment with 5-HT. A2, Confocal images of a neuron injected with both anti-tCREB1 antibody and Alexa 488-dextran and of a noninjected neuron. Neurons were incubated with secondary antibody only. In the injected neuron, tCREB1 immunoreactivity was limited to the cytoplasm, suggesting that the antibody did not cross the nuclear membrane. Minimal autofluorescence and background staining were observed in the noninjected neuron. Scale bar, 20 m. A3, EPSPs recorded from sensorimotor cocultures before (pre) and 24 h after (post) treatment with 5-HT or vehicle. In some experiments, the facilitation was so large that it led to the initiation of a spike. In these cases, the EPSP was assigned a value of 65 mV as was done in previous studies (Zhao et al., 2003) . A4, Summary data. One-way ANOVA followed by post hoc tests showed that injection of anti-tCREB1 antibody blocked LTF without significantly affecting basal transmission over 24 h. B1, Cytoplasmic injection of anti-tCREB1 antibody blocked 5-HT-induced increase in nuclear tCREB1. In the top panel of representative images, the cytoplasmic locus of fluorescein indicated antibodies were injected into the cytoplasm. In the bottom panel, tCREB1 levels in the nucleus 2 h after 5-HT treatment was measured by immunofluorescence staining using anti-tCREB1 antibody. Scale bar, 20 m. B2, Anti-tCREB1 injection blocked 5-HT-enhanced expression of tCREB1 in nucleus (n ϭ 4 independent experiments, representing 22 IgG-injected plus vehicle, 21 IgG-injected plus 5-HT, 21 anti-tCREB1-injected plus vehicle, and 23 anti-tCREB1-injected plus 5-HT neurons). C, Model of CREB1 feedback loop for the induction and consolidation of long-term memory in Aplysia (see Discussion for description). 5%; t 3 ϭ 4.432; p Ͻ 0.05, representing a total of 34 neurons). Thus, injection of anti-tCREB1 antibody does not appear to interfere with the regulation of preexisting nuclear CREB1. Furthermore, these results indicate that initial CREB1 phosphorylation at Ser-85 is not sufficient for LTF and corroborate the requirement for a CREB1-positive feedback loop in the consolidation of LTF.
Discussion
A critical role for CREB1 in the induction of long-term synaptic plasticity was demonstrated previously (Dash et al., 1990; Bartsch et al., 1998) . Dash et al. (1990) found that injecting CRE oligonucleotides to sequester and therefore functionally block endogenous CREB1 before 5-HT treatment blocked LTF. Subsequent studies by Bartsch et al. (1998) found that injection of anti-CREB1 antibodies before induction of LTF blocked facilitation at 24 h. Since that time, numerous studies in invertebrates and vertebrates have implicated CREB in long-term synaptic plasticity (for review, see Lonze and Ginty, 2002) . However, these previous experiments do not permit differentiation between a role of CREB in induction and consolidation of synaptic plasticity. By manipulating levels of CREB1 after induction, we found that CREB1 has a specific role in the consolidation phase of long-term plasticity.
Our results showed that a 5-HT treatment protocol that produces LTF led to increased levels of CREB1 mRNA both immediately and up to 24 h after 5-HT treatment. Moreover, this increased message was associated with increased expression of total and phosphorylated CREB1 protein. As suggested by previous work in our laboratory (Mohamed et al., 2005) , we found that the increase in total CREB1 is regulated by CREB1 itself, corroborating the existence of a CREB1-positive feedback loop. Could this loop drive CRE-dependent transcription for several hours after LTF induction? Little is known about transcription beyond the induction phase of LTF. Although initial experiments suggested that transcription is required only during LTF induction (Montarolo et al., 1986) , later studies supported a role for CCAAT enhancer-binding protein (C/EBP)-mediated transcription up to 9 h after 5-HT for LTF measured at 24 h (Alberini et al., 1994) . Our data support the presence of increased CRE-mediated transcription for at least 12 h after 5-HT (Fig. 1 E) . This result suggests that either ongoing transcription beyond 9 h is necessary for the consolidation of LTF but does not depend on C/EBP, or that this late transcription is required for late-LTF, which is observed at 48 and 72 h after 5-HT (Zhang et al., 1997; Casadio et al., 1999) .
The results of our experiments on the CREB1 feedback loop and its role in consolidation of LTF give rise to the following model ( Fig. 2C) : treatment with 5-HT results in enhanced recruitment of phosphorylated CREB1 to its promoter region and a concomitant decrease in the binding of the transcriptional repressor CREB2 to the CREB1 promoter region (Mohamed et al., 2005) . These changes in binding would lead to the sustained increase in CREB1 expression. In turn, the increase in CREB1 levels and its persistent phosphorylation, probably via the persistent activation of PKA (Mü ller and Carew, 1998) , would lead to further creb1 expression and thereby close the feedback loop, leading to prolonged expression of CREB1. Increased expression of CREB1 would not only lead to activation of creb1 but also of other genes that have CREs in their promoters, thus regulating the synthesis of proteins necessary for the consolidation of LTF.
The dynamics of CREB expression could explain at least in part why multiple spaced learning trials are more effective in producing long-term memory than single trials or even multiple trials when massed together (i.e., massed training) (Frost et al., 1985; Wainwright et al., 2002) . Indeed, in Aplysia, four multiple trials (five shocks per trial) separated by 24 h intervals produce memory (sensitization) that lasts for Ͼ7 d, whereas a single trial produces memory that lasts for only 4 d (Frost et al., 1985) . Our results indicate that a second trial 24 h after the first would occur at a time associated with "residual" elevation of CREB1 levels. Consequently, more CREB1 would be available to activate CRE-mediated gene expression, "boosting" gene expression above that produced by the first training trial.
An extension of this line of reasoning is that the dynamics of CREB expression could help inform the development of optimal behavioral training protocols. An understanding of the dynamics of the molecular cascades involved in the induction and consolidation of memory can be used to develop training procedures that are "in phase" with those cascades, thereby leading to enhanced learning and memory.
